Exclusive Summary

• Targets a massive global market of over 500 million cardiovascular and ischemic stroke patients, with surging demand driven by global population aging.
• Represents a "blue ocean" opportunity with no patent barriers and minimal competition from Indian or Western generic makers, enabling distributors to easily secure regional exclusivity.
• Backed by decades of extensive clinical validation in China, providing proven efficacy in microcirculation improvement as a highly cost-effective adjunctive therapy.
• Manufactured with highly mature sterile processes for the mainstream 5ml:0.1g dosage, fully supported by CTD dossiers to facilitate rapid registration in emerging markets.